Clinical Trial Update: Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating sparsentan for proteinuria associated with VEGF signaling pathway inhibitors; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proteinuria
• Proteinuria in Nephrotic Range
• Proteinuric Kidney Disease
• Proteinuric Renal Disease

Drugs mentioned

• Sparsentan (sparsentan)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Proteinuric Renal Disease, Proteinuric Kidney Disease | Phase 1 | Status: NOT_YET_RECRUITING